The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor
Flebologiia · 2015
DOI: 10.17116/flebo20159126-29 ↗Kurz gefasst
Fachartikel in der Zeitschrift Flebologiia, 2015. Verfasst von E. Yu. Soldatsky und 2 weiteren Autor:innen. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
the tolerance to dabigatran etexilate and the patients’ compliance with the prescribed treatment were estimated.
Results
None of the patient exhibited the signs of recurrent venous thromboembolism (95% confidence interval 0—14.6%). Hemorrhagic episodes during the 3 month observation period were recorded in 4 (12.5%) patients (95% confidence interval 4—30%). The cases of severe hemorrhage were totally absent. Only one (3%) patient developed an adverse reaction (tachycardia). Compliance with the prescribed therapy was estimated at 94%.
Conclusion
The application of dabigatran etexilate in the routine clinical practice has excellent prospects due to its high effectiveness and safety for the patients presenting with deep venous thrombosis.
Zitieren
APA
Soldatsky, E. Y., Lebedev, I. S., & Zolotukhin, I. A. (2015). The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor. Flebologiia. https://doi.org/10.17116/flebo20159126-29
Vancouver
Soldatsky EY, Lebedev IS, Zolotukhin IA. The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor. Flebologiia. 2015. doi:10.17116/flebo20159126-29
BibTeX
@article{Soldatsky2015,
author = {Soldatsky, E. Yu. and Lebedev, I. S. and Zolotukhin, I. A.},
title = {The treatment of deep venous thrombosis with the use of an oral thrombin inhibitor},
journal = {Flebologiia},
year = {2015},
doi = {10.17116/flebo20159126-29}
}
EUVIMED